Literature DB >> 720482

Antiparkinsonian drug doses and neuroleptic receptors.

M Titeler, P Seeman.   

Abstract

The clinical potency of 3 drugs, apomorphine, N-propylnorapomorphine, and bromocryptine, have been found to be closely correlated to their potencies in competing for 3H-haloperidol and 3H-spiroperidol both of which label the dopamine receptor. This correlation indicates that the direct binding assay may be used to predict clinical potencies of anti-parkinsonian drugs, and indicates that agonists as well as antagonists compete potently for 3H-neuroleptic binding.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 720482     DOI： 10.1007/bf01932371

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  24 in total

1.  The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states.

Authors:  I Creese; D R Burt; S H Synder
Journal:  Life Sci       Date:  1975-12-01       Impact factor: 5.037

2.  Dopamine receptor binding in the corpus striatum of mammalian brain.

Authors:  D R Burt; S J Enna; I Creese; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

3.  Studies on the antiparkinsonism efficacy of lergotrile.

Authors:  A Lieberman; T Miyamoto; A F Battista; M Goldstein
Journal:  Neurology       Date:  1975-05       Impact factor: 9.910

Review 4.  Anti-schizophrenic drugs--membrane receptor sites of action.

Authors:  P Seeman
Journal:  Biochem Pharmacol       Date:  1977-10-01       Impact factor: 5.858

5.  The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.

Authors:  J Y Lew; F Hata; T Ohashi; M Goldstein
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

6.  Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release.

Authors:  M G Caron; M Beaulieu; V Raymond; B Gagné; J Drouin; R J Lefkowitz; F Labrie
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

7.  Adrenergic -and -receptors in coronary vessels in man. An in vitro study.

Authors:  R Andersson; S Holmberg; N Svedmyr; G Aberg
Journal:  Acta Med Scand       Date:  1972-03

8.  The antiparkinsonian efficacy of bromocriptine.

Authors:  A Lieberman; M Zolfaghari; D Boal; H Hassouri; B Vogel; A Battista; K Fuxe; M Goldstein
Journal:  Neurology       Date:  1976-05       Impact factor: 9.910

9.  Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.

Authors:  J Gerlach
Journal:  Acta Neurol Scand       Date:  1976-03       Impact factor: 3.209

10.  Treatment of parkinson's disease with bromocriptine.

Authors:  A Lieberman; M Kupersmith; E Estey; M Goldstein
Journal:  N Engl J Med       Date:  1976-12-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.